MARKET EYE-Credit Suisse upgrades Dr Reddy's on US outlook

Thu Dec 13, 2012 9:15am IST

Related Topics

Stocks

   

* Credit Suisse upgrades Dr. Reddy's Laboratories to
'outperform' from 'neutral' and raises its target price to 2,150
rupees from 1,900 rupees, citing expectations for a strong pick
up in U.S. sales in the coming quarters.
* Credit Suisse also notes the market share for Dr. Reddy's
Metoprolol drug, used for hypertension, is increasing.
* Dr. Reddy's also expects upcoming approval of two limited
competition products in the United States, Credit Suisse says
after meeting with the drug maker's management.
* Dr. Reddy's also expects fiscal 2015 growth in the United
States to be stronger than fiscal 2014 due to some "significant"
launches.

 (abhishek.vishnoi@thomsonreuters.com /;
abhishek.vishnoi.reuters.com@reuters.net)
FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Fuelling Change

REUTERS SHOWCASE

NSEL Fraud

NSEL Fraud

Govt orders Financial Tech to absorb NSEL, liabilities  Full Article 

Stalemate

Stalemate

WTO prepares for crisis talks as India keeps veto on global deal.  Full Article 

Deal Talk

Deal Talk

Smartphone repair company B2X steps up expansion with Indian deal.  Full Article 

Earnings Season

Earnings Season

HDFC Bank eyes pickup in corporate credit.  Full Article 

JLR China

JLR China

JLR sees 20 percent growth in China sales this year - exec  Full Article 

Iron Ore Imports

Iron Ore Imports

JSW Steel to boost iron ore imports by up to 80 percent.  Full Article 

Pollution Levels

Pollution Levels

Delhi braces for worst air quality this Diwali week.  Full Article 

Remembering Margerie

Remembering Margerie

Total’s "Big Moustache"- bon vivant, deal-maker and risk-taker .  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage